Get the Stockscreener App
6.66
1.22%
0.08
Exagen Inc stock is traded at $6.66, with a volume of 154.19K.
It is up +1.22% in the last 24 hours and up +62.84% over the past month.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
See More
Previous Close:
$6.58
Open:
$6.58
24h Volume:
154.19K
Relative Volume:
0.44
Market Cap:
$161.34M
Revenue:
$68.38M
Net Income/Loss:
$-20.17M
P/E Ratio:
-7.5348
EPS:
-0.8839
Net Cash Flow:
$-14.13M
1W Performance:
-3.06%
1M Performance:
+62.84%
6M Performance:
+103.05%
1Y Performance:
-28.73%
1-Day Range:
$6.50
$6.695
1-Week Range:
$6.49
$6.975
52-Week Range:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
6.66 | 159.64M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results - webull.com
Agenus: Q2 Earnings Snapshot - aol.com
Exagen Inc. (XGN) Climbs 4.25% to $6.87, Holding Above Key SupportTPO Profile - dars.gov.et
Exzeo: Q2 Earnings Snapshot - AOL.com
Xenon Pharmaceuticals: Q2 Earnings Snapshot - AOL.com
Exagen Q2 2026 Earnings: Record Revenue and Reduced EBITDA Loss - sekbernews.id
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution - Yahoo Finance
XGN Maintains Buy Rating -- Price Target Raised to $10.00 by TD Cowen - GuruFocus
XGN Reiterates by B. Riley Securities -- Price Target Raised to $12 - GuruFocus
Exagen Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-08-05 - Seeking Alpha
XGN Maintained by BTIG -- Price Target Raised to $9.00 - GuruFocus
Insiders At Exagen Sold US$680k Of Stock Potentially Indicating Weakness - Moomoo
B. Riley Adjusts Price Target on Exagen to $12 From $8, Maintains Buy Rating - marketscreener.com
BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Reve - GuruFocus
Exagen: The Path To Profitability Just Became More Credible (NASDAQ:XGN) - Seeking Alpha
Exagen revenue reaches record level in Q2 2026 as test volume and ASP climb, lifts full year outlook - Traders Union
Exagen Inc. Stock 12‑Month Price Target Raised to $8.71, Implies 86% Upside - TradingView
Exagen Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability - Yahoo Finance
Exagen Q2 Earnings Call Highlights - Yahoo Finance
Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue H - GuruFocus
Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20% - Investing.com
Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance - Yahoo Finance
Exagen Q2 2026 slides: record revenue, stock surges 30% on results - Investing.com
XGN: Record revenue, improved margins, and raised guidance highlight strong execution and growth - TradingView
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Exagen Q2 2026 slides: record revenue, stock surges 36% - Investing.com
Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results - MarketBeat
Exagen Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary - TradingView
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M - Stock Titan
Q2 2026 Exagen Inc Earnings Call Transcript - GuruFocus
Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance - Moomoo
Exagen Inc. Reports Second Quarter 2026 Financial Results - The Manila Times
Exagen reports Q2 2026 revenue $19.9M, narrows adjusted EBITDA loss to $0.1M - TradingView
Exagen reports record Q2 revenue of $19.9 million - Quiver Quantitative
XGN: Record revenue and improved margins drive higher guidance and reduced losses - TradingView
BRIEF-Exagen Inc. Q2 Revenue USD 19.941 Million Vs. IBES Estimate USD 17.8 Million - TradingView
Exagen Inc. Increases Earnings Guidance for the Full Year 2026 - marketscreener.com
Exagen Q2 2026 slides: record revenue, stock surges 36% By Investing.com - Investing.com Canada
Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Escalade: Q2 Earnings Snapshot - AOL.com
Exagen Inc. to Participate in Upcoming Investor Conference - The Manila Times
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XGN|Exagen Inc|Price:4.530|Chg%:-0.140 - TradingKey
Exagen Inc (XGN) Institutional Confidence - TradingKey
Exagen Inc (XGN) Balance Sheet - TradingKey
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):